Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group

AIM: The present study aimed to determine the real‐world efficacy and safety of the non‐structural protein (NS)5A inhibitor elbasvir (EBR) combined with the NS3/4A protease inhibitor grazoprevir (GZR) in patients with hepatitis C virus (HCV) genotype 1 (GT1) infection. METHODS: This study retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashiba, Toshie, Joko, Kouji, Kurosaki, Masayuki, Ochi, Hironori, Hasebe, Chitomi, Akahane, Takehiro, Sohda, Tetsuro, Tsuji, Keiji, Mitsuda, Akeri, Kimura, Hiroyuki, Narita, Ryoichi, Ogawa, Chikara, Furuta, Koichiro, Shigeno, Masaya, Okushin, Hiroaki, Ito, Hiroshi, Kusakabe, Atsunori, Satou, Takashi, Kawanami, Chiharu, Nakata, Ryo, Kobashi, Haruhiko, Tamada, Takashi, Ide, Yasushi, Yagisawa, Hitoshi, Morita, Atsuhiro, Matsushita, Tomomichi, Okada, Kazuhiko, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899599/
https://www.ncbi.nlm.nih.gov/pubmed/31077527
http://dx.doi.org/10.1111/hepr.13362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899599/
https://www.ncbi.nlm.nih.gov/pubmed/31077527
http://dx.doi.org/10.1111/hepr.13362

Ejemplares similares